Impact BioMedical Inc. 2025 Annual Report: Key Highlights for Investors

Executive Summary

Impact BioMedical Inc. (“Impact”, “IBO”, or the “Company”) released its Annual Report for the year ended December 31, 2025. This report offers significant updates that are crucial for current and prospective shareholders, including a transformative merger, operating segment details, competitive positioning, and risk factors that could impact share value.

1. Major Strategic Development: Reverse Merger with Dr. Ashleys Limited

Impact BioMedical announced a definitive merger agreement to be acquired by Dr. Ashleys Limited in a reverse merger. This is a pivotal, price-sensitive event for shareholders, as the transaction aims to:

• Combine Dr. Ashleys’ global pharmaceutical manufacturing capabilities with Impact BioMedical’s patent portfolio.
• Create a new, stronger entity with a broader platform for revenue generation and product development.
• Accelerate new product launches and technology development.
• Maintain trading on the NYSE American, which supports liquidity and market visibility.

This merger is structured to drive near-term revenue and strengthen the Company’s competitive position.

2. Improved Financial Position and Segment Reporting

The Company reported an improved financial position for 2025, driven by new and improved technology and patent platforms, as well as strategic merger initiatives. Impact BioMedical currently operates as a single business segment, focusing on the discovery, development, and commercialization of medical and wellness solutions. The Chief Operating Decision Maker (CODM) does not allocate resources or assess performance based on segment assets, reinforcing the Company’s streamlined structure.

3. Subsidiary and Ownership Structure

• Impact BioLife Science, Inc.: Wholly owned subsidiary.
• Sweet Sense, Inc.: 95.5% owned by Impact BioMedical.

4. Intellectual Property and Technology Platforms

Impact BioMedical has a portfolio of proprietary technologies under continuous development. The company targets urgent, unmet medical needs and leverages technology and science with strategic partnerships to drive advances in drug discovery, especially for neurological, oncology, and immuno-related diseases. Notably, the Company is developing a breakthrough alternative sugar to combat diabetes and functional fragrances with industrial and medical applications.

5. Market Position and Competition

The Company operates in highly competitive markets, focusing on specialty biopharmaceuticals, antivirals, antimicrobials, and consumer wellness products, often sourced from natural elements. Impact competes against large pharmaceutical firms, biotech companies, academic institutions, and public/private research entities. The ability to attract talent, protect intellectual property, and negotiate competitive pricing is central to maintaining a leadership position.

6. Regulatory and Environmental Compliance

Impact adheres to all applicable environmental laws and regulations. Management does not anticipate that compliance will have a material adverse effect on the Company’s financial position or cash flows. However, new or changing regulations remain a risk factor for future operations.

7. Risks and Shareholder Considerations

• Liquidity and Capital: While the Company has received capital infusions and completed its IPO, additional funds may be required to meet operational and growth needs. There is no guarantee of securing the necessary funding, which could materially impact operations.
• Intellectual Property Risks: The Company’s success depends on protecting its IP. Trade secrets are difficult to protect, and the risk of unauthorized disclosure or inadequate patent protection remains.
• Market and Stock Risks:
  • The public float is relatively small, with concentrated ownership among insiders and significant shareholders. This increases price volatility and may reduce liquidity.
  • The Company does not anticipate paying dividends in the near future. Shareholder gains will depend primarily on stock price appreciation.
  • Stock price may be impacted by numerous factors, including financing activities, changes in management, industry developments, and market sentiment.
• Listing Status: The Company’s common stock is listed on the NYSE American. If it fails to meet listing requirements and is delisted, shares may become subject to “penny stock” rules, significantly reducing liquidity and potentially lowering the share price. Delisting would also mean additional compliance with state securities laws for secondary market transactions, further restricting liquidity.
• Emerging Growth Company: Impact BioMedical is classified as an “emerging growth company” and takes advantage of reduced disclosure requirements, which may make the stock less attractive to some investors. The Company can delay adoption of new accounting standards, which may affect financial comparability with peers.
• No Material Legal Proceedings: Management reports no material legal proceedings involving directors, officers, or the Company.

8. Shareholder Statistics

• Market Value of Public Float: \$7,599,000 as of June 30, 2025.
• Shares Outstanding: 107,821,231 common shares as of March 6, 2026.
• Authorized Capital: 4,000,000,000 common shares and 100,000,000 preferred shares.
• Listing: NYSE American; trading symbol not provided (N/A).

9. Other Noteworthy Items

• No Documents Incorporated by Reference: The Annual Report does not incorporate any other documents by reference.
• Company Website: www.impactbiomedinc.com — Financial filings and press releases are provided as soon as practicable after filing with the SEC.

Conclusion: Potentially Price-Moving Developments

The definitive merger agreement with Dr. Ashleys Limited is the most significant, price-sensitive development, as it is expected to accelerate revenue, bolster product offerings, and strengthen the Company’s market presence. Additionally, the Company’s improved financial position, growing patent portfolio, and strategic focus on unmet healthcare needs provide encouraging signals for the future. However, shareholders should carefully consider the risks related to liquidity, listing status, capital requirements, and market volatility.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full Annual Report and consult with financial advisors before making investment decisions. The information summarized here may be subject to change and may not reflect the most current developments. The Company’s performance and stock price are subject to various risks, many of which are outlined above.

View IMPACT BIOMEDICAL INC. Historical chart here